Autor: |
Zhuravleva, M., Khaliullin, M., Masgutov, R., Deev, R., Rizvanov, A. |
Zdroj: |
BioNanoScience; Jun2017, Vol. 7 Issue 2, p288-293, 6p |
Abstrakt: |
Though normally bone regenerates well, non-union, delayed union, or defective bone formation can occur. Since impaired healing is often caused by local trophic disorders, standard fracture management is often ineffective. Gene therapy is a promising field for bone engineering. We have created a recombinant plasmid construct encoding the genes for pro-angiogenic vascular endothelial growth factor 165A (VEGF165A) and pro-osteogenic bone morphogenetic protein 2 (BMP2) with kanamycin resistance (pBudKan-VEGF165A-BMP2). This plasmid has the potential for use in treatment of trauma and skeletal system disorders, especially in cases of low trophicity. [ABSTRACT FROM AUTHOR] |
Databáze: |
Complementary Index |
Externí odkaz: |
|